HJF to develop herpes virus vaccines
The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) and Citranvi Biosciences have signed an exclusive licensing agreement to develop vaccine technologies to prevent cytomegalovirus and Epstein-Barr virus infections.
Aridis touts positive preclinical results for COVID-19 mAb treatment
Anti-infective therapies firm Aridis Pharmaceutical has developed an inhalable highly neutralizing monoclonal antibody (mAb) that eradicated the novel coronavirus in infected rodents.
Samsung Biologics, BioEleven partner on cancer immunotherapy
Samsung Biologics has entered into a strategic partnership with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer.
Reaction Biology, 4HF Biotec offer new cell-based services
Reaction Biology and 4HF Biotec announced that they are offering a new cell-based service that will give customers a comprehensive understanding of their candidates. The service will combine Reaction's ProLiFiler cell assay service with 4HF's Biomarker Analysis and Mode of Action (MoA) Finder tools
Endo to acquire BioSpecifics
Endo will acquire all shares of BioSpecifics Technologies for $88.50 per share, or an estimated total of $540 million. As part of the acquisition, BioSpecifics will receive a royalty stream from Endo's collagenase-based therapies, including Xiaflex and Qwo, which were developed by BioSpecifics.
New methods could improve AAV quality for viral vector manufacturing
Developing well-characterized adeno-associated viral vectors (AAVs) is a significant obstacle for the biomanufacturing industry. A group of analytical researchers is trying to overcome this challenge by developing novel analytical methodology specifically designed for AAVs.  Discuss
Precigen nabs FDA nod for manufacturing UltraCAR-T therapies
Precigen has been granted clearance by the U.S. Food and Drug Administration (FDA) for its UltraPorator system. The system also had a successful technology transfer to clinical sites and will be used as a manufacturing device for Precigen's investigational UltraCAR-T therapies.
Thermo Fisher launches closed cell processing system
Thermo Fisher Scientific has launched the Gibco CTS Rotea counterflow centrifugation system, a modular, closed cell therapy processing system for cell therapy development and manufacturing.
ImmunityBio begins phase I trial for its COVID-19 vaccine candidate
ImmunityBio has been authorized by the U.S. Food and Drug Administration to begin a phase I clinical trial of its hAd5-COVID-19 vaccine candidate.
Sestina Bio to develop digital cell engineering platform
Sestina Bio, a new company developing an automated synthetic biology platform, has been launched with seed funding. Sestina also is the first company to be launched from the Foresite Labs incubator.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter